The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
|Videos|February 29, 2016
Lesley Ann Saketkoo From Tulane University: Steroids for Treating Sarcoidosis an Option but Far From Ideal
Author(s)Adam Hochron
As more is learned about the treatment of sarcoidosis there is little doubt that steroids are not the final step in the development process. Doctors and researchers are working to find what that next step is.
Advertisement
As more is learned about the treatment of sarcoidosis there is little doubt that steroids are not the final step in the development process. Doctors and researchers are working to find what that next step is.
Lesley Ann Saketkoo, MD, MPH, from Tulane University discussed how new treatments are being developed for the condition now and what it means for patients dealing with the condition on a daily basis today.
Advertisement
Related to this article
Amgen reported dazodalibep met its primary endpoint in the phase 3 OASIZ-301 trial, improving ESSDAI score in moderate-to-severe systemic Sjögren's disease.
Rozanolixizumab improved FIQR score at 10 weeks but did not reach 2-sided statistical significance on its primary BPI-SF interference endpoint.
Two-year data from the open-label extension show sustained ACR and MDA response rates for the TYK2 inhibitor in active psoriatic arthritis.
Oberlin outlines what dermatologists should weigh, beyond APEX's radiographic data, when selecting a biologic for PsA.
Beeline Medicines reported positive topline data meeting primary SRI-4 endpoint at week 48 across all 3 doses in systemic lupus erythematosus.
The designation follows phase 2 IMPACT trial data showing reduced adverse pregnancy outcomes in high-risk antiphospholipid syndrome.
In a large real-world PsA cohort, higher BMI reduced the odds of minimal disease activity, especially with TNF inhibitors other than infliximab.
Advertisement
Advertisement